MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

EQS-News: MorphoSys AG


/ Key word: Change in Forecast





MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022






21.10.2022 / 11:41... | October 21, 2022

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Canada ,United Kingdom ,Planegg ,Bayern ,Kaitlyn Nealy ,Thomas Biegi ,Julia Neugebauer ,Jean Paul Kress ,Exchange Commission ,Linkedin ,Xencor Inc ,Twitter ,Drug Administration ,Nasdaq ,Updates Financial Guidance ,Product Sales ,Chief Executive Officer ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Morphosy Annual Report ,Morphosys Ag Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Key ,Change ,N ,Reports ,Reliminary ,3 ,022 ,Monjuvi ,Sales ,End ,Updates ,Financial ,Guidance ,Or ,022 Mor De0006632003 ,